Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.30 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.30 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956232 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL8119809 | 0.77 | — | — | |
| SCHEMBL3962219 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL4062543 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL28821719 | 0.76 | — | — | |
| SCHEMBL6527341 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL27482372 | 0.74 | — | — | |
| SCHEMBL4032174 | 0.70 | HTT (0.44) | LMNAHTT | |
| SCHEMBL3070359 | 0.69 | NOTUM (0.33) | — | |
| SCHEMBL10600899 | 0.65 | CYP2D6 (0.38) | LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | EGLN2 1462/4885EGLN1 1228/4885EGLN3 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.